secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K
Filed at:   2023-11-30T23:59:59+00:00
Accession:  0001493152-23-043219
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Nasdaq grants Vivos extension to March 19, 2024 for equity compliance; delisting risk persists
--------------------------------------------------------------------------------

- Regained minimum bid price compliance on Nov 9, 2023 after 1-for-25 reverse stock split.
- Nasdaq Panel granted extension until March 19, 2024 to meet $2.5M minimum stockholders' equity requirement.
- Company raised ~$4M in private placement but warns additional capital may be needed; failure risks delisting.
- Must provide compliance update by Jan 31, 2024; non-compliance could restart delisting proceedings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000149315223043219/0001493152-23-043219-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000149315223043219/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-043219

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer